Technologies
Our Licensing Portfolio
RCT has developed and invested in relevant life science technologies that enable novel therapeutics, support research and development across the life sciences, and facilitate manufacturing processes worldwide. We primarily commercialize our life science technologies through licensing programs that offer either exclusive or non-exclusive rights. Our portfolio of life science technologies includes:
- bgh Polyadenylation Signal
- Blue Noise Mask
- Cisplatin and Carboplatin Anticancer Drugs
- Deimmunized Sarcin Ribotoxin
- Endotoxin-free ClearColi™ Expression System
- Fibronectin Artificial Antibody Scaffold
- Fullerenes
- Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)
- mRNA Transport Enhancer
- PEGylation: Non-Immunogenic Delivery of Protein-Based Drugs
- Pichia Classic Expression Platform
- Pichia GlycoSwitch® Protein Expression System
- Pichia Protein Expression System
- Prostate-Specific Antigen Blood Test for Prostate Cancer
- Shingles Vaccine Antigen
- Silver Sulfadiazine Burn Ointment
- Technetium-99M Complexes for Cardiac Imaging
- The CH2 Domain Scaffold – ABDURINS™
- Ultrasound Tissue Harmonic Imaging
- VIMPAT® (lacosamide) for Treatment of Epileptic Seizures
- Viral-mediated Gene Transfer System
Our Interests
RCT seeks new or existing patented life science technologies that can generate fees, milestones and royalties through an active licensing program. Our interests include platforms for the discovery, development, formulation, and manufacturing of therapeutics, diagnostics and industrial biotech products. Areas where we have specific interests include:
- Molecular Biology Tools
- Novel Vectors, Promoters, and Genetic Control Elements
- Protein Expression Systems
- Protein and Nucleic Acid Delivery Systems
- Novel Drug Scaffolds and Binders
- Protein Display Technologies
- Drug Screening Tools
- Drug Formulation Platforms
Related News & Events
- 12.3.2018: UCB announces approval of VIMPAT® in China
- 5.23.2018: U.S. COURT OF APPEALS CONFIRMS THE VALIDITY RCT’S PATENT COVERING VIMPAT® (LACOSAMIDE)
- 11.6.2017: UCB’s VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients
- 12.3.2014: RCT and VTU Technology Partner to Offer Custom Glycoprotein Production in Pichia GlycoSwitch
- 6.4.2013: RCT and BioGrammatics Announce Partnership, Launch of the Pichia pastoris GlycoSwitch® Expression System